In Q1 2026, the Biotech & Pharma industry crossed a threshold most boardrooms missed. An AI-designed molecule demonstrated clinical efficacy in a controlled human trial for the first time. Simultaneously, the BIOSECURE Act restructured who can participate in US-funded research, and $84 billion in M&A confirmed the market had already priced in the value of AI-accelerated pipelines. None of this required insider access. It required reading the signals together.